Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
191.49B
Market cap191.49B
Price-Earnings ratio
24.97
Price-Earnings ratio24.97
Dividend yield
2.72%
Dividend yield2.72%
Average volume
2.56M
Average volume2.56M
High today
$357.61
High today$357.61
Low today
$349.42
Low today$349.42
Open price
$353.63
Open price$353.63
Volume
3.69M
Volume3.69M
52 Week high
$391.29
52 Week high$391.29
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $355.99. The company's market cap stands at 191.49B, with a P/E ratio of 24.97 and a dividend yield of 2.7%.

On 2026-04-18, Amgen(AMGN) stock moved within a range of $349.42 to $357.61. With shares now at $355.99, the stock is trading +1.9% above its intraday low and -0.5% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 3.69M, versus its average volume of 2.56M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

Simply Wall St 1d
Assessing Whether Amgen Still Looks Undervalued After Recent Share Price Pullback

Advertisement Context for Amgen (AMGN) after recent price moves Recent trading in Amgen (AMGN) has drawn attention after a modest 0.3% gain over the past day...

Assessing Whether Amgen Still Looks Undervalued After Recent Share Price Pullback
TipRanks 3d
Limited Near-Term Growth and Patent Headwinds Drive Underperform Rating on Amgen

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Sell rating on Amgen, retaining the price target of $304.00. Unlock hedge fund-level data and p...

Simply Wall St 4d
Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story

Amgen (NasdaqGS:AMGN) and Zai Lab have agreed to a global clinical trial collaboration focused on small cell lung cancer. The partnership will evaluate a combi...

Amgen And Zai Lab DLL3 Alliance Adds New Dimension To Oncology Story

Analyst ratings

51%

of 37 ratings
Buy
40.5%
Hold
51.4%
Sell
8.1%

More AMGN News

TipRanks 5d
Amgen price target raised to $400 from $390 at UBS

UBS raised the firm’s price target on Amgen (AMGN) to $400 from $390 and keeps a Buy rating on the shares. The firm adjusted targets in the pharmaceuticals and...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.